Management of Irritable Bowel Syndrome with Constipation (IBS-C)

Symptoms of IBS-C

IBS-C presents with recurrent abdominal pain associated with constipation, typically requiring symptoms present for at least 12 weeks in the past 12 months. 1

Key diagnostic features include:

Abdominal pain or discomfort that is relieved by defecation, associated with change in stool frequency, or associated with change in stool consistency 1
Constipation symptoms: fewer than 3 bowel movements per week, hard or lumpy stools (Bristol Stool Form Scale types 1-2), straining during defecation, sensation of incomplete evacuation 1
Abdominal bloating and distension are extremely common, reported by patients as frequent and often more bothersome than pain itself 1
Non-gastrointestinal symptoms that support the diagnosis include lethargy, poor sleep, fibromyalgia, backache, urinary frequency, and dyspareunia 1

The diagnosis can be made confidently in patients under 45 years with typical symptoms, no alarm features (weight loss, rectal bleeding, nocturnal symptoms, anemia), and normal physical examination without extensive testing 1

Step-by-Step Management Strategy

Step 1: Foundational Lifestyle Interventions (Start Immediately)

Begin with regular physical exercise as this improves global IBS symptoms and forms the foundation of all treatment. 2

Dietary counseling: Establish regular meal patterns (eating at consistent times), ensure adequate hydration (6-8 glasses of water daily), limit caffeine and alcohol intake, and reduce gas-producing foods 2
Avoid insoluble fiber entirely (wheat bran, whole grain breads) as it consistently worsens IBS-C symptoms, particularly bloating 2
Ensure adequate time for defecation: Patients must allow suitable and regular time for bowel movements, especially after meals when the gastrocolic reflex is strongest 1

Step 2: First-Line Pharmacological Treatment

Start soluble fiber supplementation with psyllium (Metamucil) or methylcellulose (Citrucel) as the initial pharmacological intervention. 2

Psyllium (Metamucil) Dosing:

Initial dose: 3-4 grams once daily, taken with at least 8 ounces of water 2
Titration: Increase gradually by 3-4 grams every 3-5 days to avoid bloating and gas 2
Target dose: Build up to 10-15 grams daily, divided into 2-3 doses 2
Duration: Trial for 4-6 weeks before declaring failure 2

If soluble fiber fails after 4-6 weeks, add polyethylene glycol (MiraLAX) as the next step. 1, 2

Polyethylene Glycol (MiraLAX) Dosing:

Initial dose: 17 grams (one capful) dissolved in 8 ounces of liquid once daily 1
Titration: Can increase to twice daily if needed after 1 week 1
Goal: Achieve 1 non-forced bowel movement every 1-2 days 2
Duration: Trial for 4 weeks before escalating therapy 2

Step 3: Second-Line Prescription Therapy (If Steps 1-2 Fail)

Linaclotide (Linzess) 290 mcg once daily is the preferred second-line agent when first-line therapies fail, as it addresses both abdominal pain and constipation with the strongest evidence. 1, 2

Linaclotide (Linzess) Dosing:

Dose: 290 mcg once daily 1, 3
Administration: Take on an empty stomach at least 30 minutes before the first meal of the day 3, 4
Mechanism: Activates guanylate cyclase-C receptors, increasing intestinal fluid secretion and accelerating transit while also reducing visceral pain 4, 5
Efficacy: 33.7% of patients achieve FDA responder criteria (≥30% reduction in abdominal pain AND ≥1 complete spontaneous bowel movement increase per week for ≥6 of 12 weeks) versus 13.9% with placebo 4
Onset: Effects observed within the first week and sustained throughout treatment 5
Duration: Review efficacy after 3 months (12 weeks) and discontinue if no response 2

Critical Side Effects and Warnings:

Diarrhea is the most common adverse event (16% with linaclotide vs 5% with placebo), occurring as the mechanism of action 3, 4
Severe diarrhea reported in 2% of patients; if this occurs, suspend dosing immediately and rehydrate the patient 3
Post-marketing reports include severe diarrhea with dizziness, syncope, hypotension, and electrolyte abnormalities (hypokalemia, hyponatremia) requiring hospitalization 3
Contraindicated in patients under 2 years of age due to risk of serious dehydration and death 3

Continue psyllium alongside linaclotide as they work synergistically—psyllium has demonstrated efficacy for global IBS symptoms and can complement secretagogue therapy. 2

Step 4: Third-Line Therapy for Refractory Abdominal Pain

If abdominal pain persists despite adequate treatment of constipation, add tricyclic antidepressants (TCAs) as neuromodulators. 1, 2

Amitriptyline Dosing:

Initial dose: 10 mg once daily at bedtime 2
Titration: Increase by 10 mg weekly as tolerated 2
Target dose: 30-50 mg once daily 2
Duration: Continue for at least 6 months if symptomatic response occurs 2
Patient counseling: Explain that TCAs are used as gut-brain neuromodulators for pain, not for depression 1, 2

Critical caveat: TCAs can worsen constipation through anticholinergic effects, so ensure adequate laxative therapy (polyethylene glycol) is maintained. 2

If TCAs worsen constipation or are not tolerated, switch to SSRIs (such as citalopram 10-20 mg daily or sertraline 25-50 mg daily) as they have fewer anticholinergic effects. 1, 2

Step 5: Psychological Therapies for Persistent Symptoms

Consider cognitive-behavioral therapy (CBT) specific for IBS or gut-directed hypnotherapy when symptoms persist despite 12 months of pharmacological treatment. 1, 2

These interventions have low risk of harm and build lifelong management skills, so early adoption is reasonable if patients are willing 1
Psychological therapies are particularly effective when patients relate symptom exacerbations to stressors or have associated anxiety/depression 1

Critical Pitfalls to Avoid

Never prescribe anticholinergic antispasmodics (dicyclomine, hyoscyamine) in IBS-C patients as they reduce intestinal motility and enhance water reabsorption, which will worsen the constipation 2

Never start with insoluble fiber (wheat bran) as it will worsen symptoms, particularly bloating 2

Never use docusate (Colace) as it lacks efficacy for constipation—evidence demonstrates no additional benefit compared to placebo 2

Never recommend IgG antibody-based food elimination diets as they lack evidence and may lead to unnecessary dietary restrictions 2

Never recommend gluten-free diets unless celiac disease has been confirmed with positive antiendomysial antibodies or tissue transglutaminase antibodies 2

Never promise complete symptom resolution—manage expectations by explaining that the goal is symptom relief and improved quality of life, not cure 1, 2

Never perform extensive investigations once IBS-C is diagnosed based on symptom criteria in the absence of alarm features, as this undermines patient confidence in the diagnosis 1, 2

When to Refer to Gastroenterology

Refer when there is diagnostic doubt, severe symptoms refractory to first-line treatments after 12 weeks, or presence of alarm features (age >45 with new-onset symptoms, rectal bleeding, unintentional weight loss, nocturnal symptoms, family history of colon cancer, anemia). 1, 2

Help us tailor your experience